Improving
glioblastoma
multiforme
GBM
treatment
radio-chemotherapy
Topotecan
growth inhibition
human
glioma
brain
study
assessed
combination
radiotherapy
days
topotecan
days
weeks
adults
histologically
untreated
GBM
incidence
non-hematological toxicities
low
grade 3-4
hematological
toxicities
patients
lymphopenia
neutropenia
Partial response
stabilization
rates
progression
weeks
overall survival
OS
rate
median
OS
weeks
Topotecan
combination
radiotherapy
tolerated
response
stabilization
patients
study
increased
benefits
survival
patients
unresectable
GBM
